Cetuximab-dependent ADCC in cancer: dream or reality?
作者信息
Ottaiano Alessandro, Scala Stefania, Iaffaioli Vincenzo Rosario
出版信息
Cancer Immunol Immunother. 2010 Oct;59(10):1607-8; author reply 1609-10. doi: 10.1007/s00262-010-0884-3. Epub 2010 Jun 25.
Abstract
摘要
相似文献
1
Cetuximab-dependent ADCC in cancer: dream or reality?西妥昔单抗依赖的癌症中的抗体依赖细胞介导的细胞毒性作用：梦想还是现实？
Cancer Immunol Immunother. 2010 Oct;59(10):1607-8; author reply 1609-10. doi: 10.1007/s00262-010-0884-3. Epub 2010 Jun 25.
2
FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck.FcγRIIIa基因多态性与西妥昔单抗诱导的头颈部鳞状细胞癌细胞毒性
Cancer Immunol Immunother. 2009 Jul;58(7):997-1006. doi: 10.1007/s00262-008-0613-3. Epub 2008 Nov 1.
3
Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma.抗表皮生长因子受体抗体西妥昔单抗治疗恶性胸膜间皮瘤的疗效。
Int J Oncol. 2012 Nov;41(5):1610-8. doi: 10.3892/ijo.2012.1607. Epub 2012 Aug 24.
4
Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients.CD56 阳性细胞对一线转移性结直肠癌患者接受西妥昔单抗治疗疗效的推测性贡献。
BMC Cancer. 2010 Jun 30;10:340. doi: 10.1186/1471-2407-10-340.
5
KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.KRAS 突变使人类结直肠癌细胞对西妥昔单抗的抗体依赖性细胞细胞毒性产生耐药性。
Int J Cancer. 2014 May 1;134(9):2146-55. doi: 10.1002/ijc.28550.
6
Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.来那度胺增强实体瘤细胞体外抗体依赖的细胞细胞毒性：宿主免疫和肿瘤标志物的影响。
Cancer Immunol Immunother. 2011 Jan;60(1):61-73. doi: 10.1007/s00262-010-0919-9. Epub 2010 Sep 17.
7
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).细胞毒性药物上调结肠癌细胞中表皮生长因子受体（EGFR）的表达，并增强其对 EGFR 靶向抗体依赖性细胞介导的细胞毒性（ADCC）的敏感性。
Eur J Cancer. 2010 Jun;46(9):1703-11. doi: 10.1016/j.ejca.2010.03.005.
8
GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.GA201（RG7160）：一种新型的、人源化的、糖基化工程化的抗 EGFR 抗体，与西妥昔单抗相比，具有增强的 ADCC 和优异的体内疗效。
Clin Cancer Res. 2013 Mar 1;19(5):1126-38. doi: 10.1158/1078-0432.CCR-12-0989. Epub 2012 Dec 3.
9
IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab.免疫球蛋白G（IgG）亚型、糖基化和表皮生长因子受体（EGFR）表达决定了西妥昔单抗在体外诱导抗体依赖性细胞毒性的作用。
Hum Antibodies. 2010;19(4):89-99. doi: 10.3233/HAB-2010-0232.
10
Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma.西妥昔单抗诱导针对表达表皮生长因子受体的食管鳞状细胞癌的抗体依赖性细胞毒性。
Int J Cancer. 2007 Feb 15;120(4):781-7. doi: 10.1002/ijc.22370.
引用本文的文献
1
Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model.西妥昔单抗在裸鼠结直肠癌异种移植模型中增强了过继性自然杀伤细胞的抗体依赖性细胞介导的细胞毒性（ADCC）活性。
Oncol Lett. 2016 Sep;12(3):1868-1876. doi: 10.3892/ol.2016.4835. Epub 2016 Jul 11.
2
[Immunotherapy for non-small cell lung cancer--novel approaches to improve patient outcome].[非小细胞肺癌的免疫疗法——改善患者预后的新方法]
Zhongguo Fei Ai Za Zhi. 2013 Apr;16(4):C9-20. doi: 10.3779/j.issn.1009-3419.2013.04.09.
3
Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome.晚期结直肠癌患者 Fc 受体 IIIa 多态性与抗 EGFR 抗体的反应和临床结局相关。
J Transl Med. 2012 Nov 21;10:232. doi: 10.1186/1479-5876-10-232.
本文引用的文献
1
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.放疗联合西妥昔单抗治疗局部晚期头颈部癌：III 期随机试验的 5 年生存数据，以及西妥昔单抗诱导皮疹与生存的关系。
Lancet Oncol. 2010 Jan;11(1):21-8. doi: 10.1016/S1470-2045(09)70311-0. Epub 2009 Nov 10.
2
Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses.肿瘤免疫抑制环境：对肿瘤特异性和非肿瘤抗原免疫反应的影响。
Expert Rev Anticancer Ther. 2009 Sep;9(9):1317-32. doi: 10.1586/era.09.88.
3
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells.多态性Fcγ受体IIIa和表皮生长因子受体表达水平在西妥昔单抗介导的、自然杀伤细胞依赖性的头颈部鳞状细胞癌细胞体外细胞毒性中的作用
Cancer Immunol Immunother. 2009 Nov;58(11):1853-64. doi: 10.1007/s00262-009-0697-4. Epub 2009 Mar 25.
4
Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.FcγRIIa-FcγRIIIa基因多态性和KRAS突变对接受西妥昔单抗联合伊立替康治疗的转移性结直肠癌患者临床结局的影响
J Clin Oncol. 2009 Mar 1;27(7):1122-9. doi: 10.1200/JCO.2008.18.0463. Epub 2009 Jan 21.
5
Platinum-based chemotherapy plus cetuximab in head and neck cancer.铂类化疗联合西妥昔单抗治疗头颈癌。
N Engl J Med. 2008 Sep 11;359(11):1116-27. doi: 10.1056/NEJMoa0802656.
6
The biological properties of cetuximab.西妥昔单抗的生物学特性。
Crit Rev Oncol Hematol. 2008 Nov;68(2):93-106. doi: 10.1016/j.critrevonc.2008.07.006. Epub 2008 Aug 3.
7
Cetuximab: appraisal of a novel drug against colorectal cancer.西妥昔单抗：一种新型抗结直肠癌药物的评估
Recent Results Cancer Res. 2007;176:135-43. doi: 10.1007/978-3-540-46091-6_11.
8
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.西妥昔单抗单药治疗及西妥昔单抗联合伊立替康治疗伊立替康难治性转移性结直肠癌。
N Engl J Med. 2004 Jul 22;351(4):337-45. doi: 10.1056/NEJMoa033025.
9
Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer.赫赛汀介导的胃癌患者抗体依赖性细胞毒性受损。
Cancer Res. 2002 Oct 15;62(20):5813-7.
Zotero 插件